Metropolis Healthcare Ltd

Metropolis Healt Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Metropolis Healthcare Ltd

₹ 424 -2.25%
01 Apr 12:37 p.m.
metropolisindia.com BSE: 542650 NSE: METROPOLIS
About

Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.

Key Points

Leading Diagnostics company[1] Metropolis Healthcare Ltd is the second largest Diagnostic company in India and the largest player in Western and Southern India.

Website BSE NSE
  • Market Cap ₹ 8,791 Cr.
  • Current Price ₹ 424
  • High / Low ₹ 566 / 329
  • Stock P/E 50.3
  • Book Value ₹ 69.1
  • Dividend Yield 0.23 %
  • ROCE 14.7 %
  • ROE 11.5 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • The company has delivered a poor sales growth of 9.22% over past five years.
  • Company has a low return on equity of 12.8% over last 3 years.
  • Dividend payout has been low at 14.9% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Service Provider

Part of BSE 500 BSE Healthcare BSE Allcap BSE 250 SmallCap Index BSE 400 MidSmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
285 283 277 308 291 331 313 350 323 345 386 429 406
215 212 214 234 226 251 235 260 251 283 296 321 311
Operating Profit 70 70 63 75 65 80 79 90 72 62 90 108 95
OPM % 25% 25% 23% 24% 22% 24% 25% 26% 22% 18% 23% 25% 23%
7 1 3 1 2 3 2 3 3 7 8 1 -0
Interest 6 6 6 6 5 6 5 5 5 5 5 6 6
Depreciation 23 23 21 22 25 26 26 27 28 29 31 32 32
Profit before tax 48 42 39 48 37 51 51 61 42 36 61 71 57
Tax % 25% 20% 26% 26% 26% 28% 25% 24% 26% 19% 26% 26% 26%
36 33 29 36 27 37 38 47 31 29 45 53 42
EPS in Rs 1.75 1.63 1.41 1.73 1.33 1.78 1.85 2.27 1.53 1.41 2.17 2.54 2.00
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
388 456 475 545 647 761 856 998 1,228 1,148 1,208 1,331 1,566
285 339 359 405 467 559 619 708 880 855 920 1,023 1,211
Operating Profit 104 117 116 140 181 203 237 290 348 293 288 308 355
OPM % 27% 26% 24% 26% 28% 27% 28% 29% 28% 26% 24% 23% 23%
10 7 29 39 6 8 -17 12 34 15 9 15 15
Interest 3 2 2 2 4 4 13 12 25 32 28 24 21
Depreciation 16 21 17 17 19 20 39 46 63 89 94 109 124
Profit before tax 95 101 128 160 164 187 169 244 293 188 175 191 225
Tax % 34% 33% 36% 33% 32% 34% 24% 25% 27% 24% 26% 24%
63 68 82 107 112 124 128 183 215 143 128 146 169
EPS in Rs 14.32 15.44 20.10 26.61 27.29 5.99 6.29 8.95 10.46 6.98 6.24 7.00 8.12
Dividend Payout % 2% 0% 100% 49% 0% 55% 32% 22% 19% 29% 16% 0%
Compounded Sales Growth
10 Years: 11%
5 Years: 9%
3 Years: 3%
TTM: 19%
Compounded Profit Growth
10 Years: 9%
5 Years: -1%
3 Years: -12%
TTM: 15%
Stock Price CAGR
10 Years: %
5 Years: -4%
3 Years: 12%
1 Year: 14%
Return on Equity
10 Years: 20%
5 Years: 17%
3 Years: 13%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 10 10 10 10 10 10 10 10 10 10 10 10 10
Reserves 292 352 269 314 405 408 513 696 876 978 1,086 1,321 1,422
20 14 5 1 1 18 67 112 379 266 197 204 201
69 87 107 188 110 113 160 181 256 240 254 324 359
Total Liabilities 391 462 391 512 526 550 750 1,000 1,521 1,495 1,547 1,859 1,993
149 153 142 202 207 213 296 343 1,059 1,121 1,177 1,447 1,573
CWIP 1 0 1 1 0 6 3 0 6 20 0 0 0
Investments 132 168 101 142 102 33 14 10 16 15 55 71 21
109 141 147 167 216 298 437 647 440 340 316 341 399
Total Assets 391 462 391 512 526 550 750 1,000 1,521 1,495 1,547 1,859 1,993

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
77 69 91 102 104 90 215 249 253 247 264 263
-61 -56 96 -86 1 36 -104 63 -736 48 -89 -199
-14 -9 -174 -17 -87 -118 -55 -33 163 -292 -181 -87
Net Cash Flow 2 4 14 -1 18 8 56 279 -321 3 -6 -23
Free Cash Flow 53 46 79 45 90 67 179 221 223 195 200 196
CFO/OP 103% 87% 113% 109% 89% 78% 118% 106% 96% 102% 105% 99%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 47 57 54 54 57 66 55 45 40 39 38 41
Inventory Days 47 52 46 38 53 55 44 59 68 64 58 65
Days Payable 75 92 96 97 88 90 152 160 136 136 150 171
Cash Conversion Cycle 19 17 3 -5 21 30 -54 -56 -29 -33 -53 -65
Working Capital Days 22 32 8 -27 28 33 2 -9 -26 -22 -16 -18
ROCE % 28% 34% 46% 43% 43% 40% 36% 29% 17% 16% 15%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Clinical Laboratories
Number

Log in to view insights

Please log in to see hidden values.

Login
Number of Patient Visits (Millions)
Millions
Number of Tests Conducted (Millions)
Millions
Service Network points (Collection Centers/PSCs/ARCs)
Number
Revenue Per Patient (RPP)
INR

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
49.75% 49.75% 49.75% 49.74% 49.67% 49.62% 49.43% 49.40% 48.89% 48.89% 48.89% 48.87%
25.67% 25.66% 24.29% 21.66% 18.90% 18.25% 18.56% 16.73% 15.29% 12.83% 12.52% 11.68%
13.64% 14.89% 16.86% 20.73% 24.86% 27.42% 28.02% 30.00% 30.30% 32.40% 33.10% 34.73%
10.94% 9.69% 9.10% 7.87% 6.57% 4.69% 3.98% 3.86% 5.51% 5.87% 5.48% 4.69%
No. of Shareholders 84,26989,69286,24979,87868,28358,10851,85248,57249,29350,01547,84646,670

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls